TY - JOUR T1 - Contribution of DNA Double-strand Break Repair Gene <em>XRCC3</em> Genotypes to Triple-negative Breast Cancer Risk JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 359 LP - 367 VL - 12 IS - 6 AU - CHEN-HSIEN SU AU - WEN-SHIN CHANG AU - PEI-SHIN HU AU - CHIEH-LUN HSIAO AU - HONG-XUE JI AU - CHENG-HSI LIAO AU - TE-CHENG YUEH AU - CHIN-LIANG CHUANG AU - CHIA-WEN TSAI AU - CHIN-MU HSU AU - HSIEN-YUAN LANE AU - DA-TIAN BAU Y1 - 2015/11/01 UR - http://cgp.iiarjournals.org/content/12/6/359.abstract N2 - Aim: The DNA-repair gene X-ray repair cross-complementing group 3 (XRCC3) is important in DNA double-strand break repair and plays a critical part in initiation of carcinogenesis. Triple-negative breast cancer (TNBC) is the most difficult breast cancer subtype with no existing gene-targeting drugs and little knowledge on its genetic etiology. This study aimed to investigate the contribution of the XRCC3 genotype to individual TNBC susceptibility. Materials and Methods: A total of 2,464 Taiwan citizens consisting of 1,232 breast cancer cases and 1,232 controls were enrolled in this case–control study, and genotyping of XRCC3 rs1799794, rs45603942, rs861530, rs3212057, rs1799796, rs861539 and rs28903081 were performed with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). We also conducted risk-stratified sub-group analyses to determine the association between the genotype and age- and hormone-related characteristics of breast cancer sub-groups. Results: There was no significant difference between breast cancer and control groups in the distributions of the genotypic or allelic frequencies as for the XRCC3 rs1799794 (p=0.5195 and 0.9545), rs45603942 (p=0.3478 and 0.1449), rs861530 (p=0.4567 and 0.5081), rs3212057 (p=1.0000 and 1.0000), rs1799796 (p=0.8487 and 0.7315) and rs28903081 (p=1.0000 and 1.0000), respectively. However, the XRCC3 rs861539 TT genotype was more prevalent in patients with breast cancer [odds ratio (OR)=2.99, 95% confidence interval (CI)=1.62-5.55; p=0.0002], and especially among those who were younger than 55 years (OR=2.61, 95% CI=1.82-3.73; p=0.0001), with first menarche earlier than 12.2 years (OR=2.47, 95% CI=1.74-3.52; p=0.0001), with menopause at 49.0 years old or later (OR=2.53, 95% CI=1.76-3.62; p=0.0001), or with TNBC (OR=2.05, 95% CI=1.46-4.28; p=4.63*10−4). Conclusion: XRCC3 rs861539 TT is a potential predictive marker for TNBC in Taiwanese women and investigations in other populations are warranted for further universal application in cancer detection and prediction. ER -